1
|
Khan KA, Ahmad A, Marini C, Nicotra M, Di Cerbo A, Fazal-Ur-Rehman, Ullah N, Khan GM. Formulation and Preparation of Losartan-Potassium-Loaded Controlled-Release Matrices Using Ethocel Grade 10 to Establish a Correlation between In Vitro and In Vivo Results. Pharmaceutics 2024; 16:186. [PMID: 38399247 PMCID: PMC10893290 DOI: 10.3390/pharmaceutics16020186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Revised: 01/22/2024] [Accepted: 01/23/2024] [Indexed: 02/25/2024] Open
Abstract
In the current study, matrices of losartan potassium were formulated with two different polymers (Ethocel 10 premium and Ethocel 10FP premium), along with a filler and a lubricant, at different drug-to-polymer w/w ratios (10:3, 10:4, and 10:5). The matrices were tested by the direct compression method, and their hardness, diameter, thickness, friability, weight variation, content uniformity, and in vitro dissolution tests were assessed to determine 24-h drug release rates. The matrices with Ethocel 10 FP at a 10:4 ratio exhibited pseudo-zero-order kinetics (n-value of 0.986), while the dissolution data of the test matrices and reference tablets did not match. The new test-optimized matrices were also tested in rabbits, and their pharmacokinetic parameters were investigated: half-life (11.78 ± 0.018 h), Tmax (2.105 ± 1.131 h), Cmax (205.98 ± 0.321 μg/mL), AUCo (5931.10 ± 1.232 μg·h/mL), AUCo-inf (7348.46 ± 0.234 μg·h/mL), MRTo-48h (17.34 ± 0.184 h), and Cl (0.002 ± 0.134 mL/min). A correlation value of 0.985 between the in vitro and in vivo results observed for the test-optimized matrices was observed, indicating a level-A correlation between the percentage of the drug released in vitro and the percentage of the drug absorbed in vivo. The matrices might improve patient compliance with once-a-day dosing and therapeutic outcomes.
Collapse
Affiliation(s)
- Kamran Ahmad Khan
- Gomal Centre of Pharmaceutical Sciences, Faculty of Pharmacy, Gomal University, Dera Ismail Khan P.O. Box 29050, Pakistan;
| | - Ashfaq Ahmad
- Riphah Institute of Pharmaceutical Sciences, Riphah International University, Gulberg Greens Campus, Islamabad P.O. Box 44000, Pakistan;
| | - Carlotta Marini
- School of Biosciences and Veterinary Medicine, University of Camerino, 62024 Matelica, Italy; (C.M.); (M.N.)
| | - Mario Nicotra
- School of Biosciences and Veterinary Medicine, University of Camerino, 62024 Matelica, Italy; (C.M.); (M.N.)
| | - Alessandro Di Cerbo
- School of Biosciences and Veterinary Medicine, University of Camerino, 62024 Matelica, Italy; (C.M.); (M.N.)
| | - Fazal-Ur-Rehman
- Gomal Centre of Pharmaceutical Sciences, Faculty of Pharmacy, Gomal University, Dera Ismail Khan P.O. Box 29050, Pakistan;
| | - Naveed Ullah
- Department of Pharmacy, University of Swabi, Swabi P.O. Box 23430, Pakistan;
| | - Gul Majid Khan
- Islamia College University, Peshawar P.O. Box 25120, Pakistan;
| |
Collapse
|
2
|
Song Q, Jiang C, Wang C, Zhou L, Han Z, Sun N, Huang P, Wang D. Preparation and in Vitro Evaluation of Osmotic-Pump Lorcaserin-hydrochloride Controlled-Release Tablets. Chem Pharm Bull (Tokyo) 2022; 70:202-210. [PMID: 35228384 DOI: 10.1248/cpb.c21-00788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Long-term and constant-release osmotic-pump lorcaserin hydrochloride controlled-release tablets (OP LH CRTs) were prepared, to investigate the influencing factors of LH release and optimize the formulation. The mechanism of release of LH from OP LH CRTs in vitro was investigated. By establishing a high-efficiency method for measuring LH release in vitro, and optimizing it by single-factor and orthogonal experiments, the best formulation of OP LH CRTs was determined. Then, the optimal prescription of OP LH CRTs was: LH = 20.8 mg; mannitol = 100 mg, microcrystalline cellulose = 125 mg; magnesium stearate = 5 mg; cellulose acetate = 3%; polyethylene glycol 400 = 10%; dibutyl phthalate = 10%; Wetting agent and binder was 3% polyvinyl pyrrolidone (PVP) K30 ethanol solution; aperture diameter = 0.8 mm; the coating gained 3% weight. And finally, prepared OP LH CRTs were released at a constant rate in vitro and sustained for 16 h with good reproducibility between batches. Using an orthogonal experimental design, OP LH CRTs with remarkable zero-order release characteristics within 16 h were obtained, and formulation optimization was realized.
Collapse
Affiliation(s)
- Qiqi Song
- School of Pharmacy, Anhui University of Chinese Medicine
| | - Chengjun Jiang
- School of Pharmacy, Anhui University of Chinese Medicine.,Shanghai Mosim Pharmaceutical Technology CO., LTD
| | - Chongyang Wang
- School of Pharmacy, Anhui University of Chinese Medicine
| | - Li Zhou
- School of Pharmacy, Anhui University of Chinese Medicine
| | - Zhili Han
- School of Pharmacy, Anhui University of Chinese Medicine
| | - Nianxia Sun
- School of Pharmacy, Anhui University of Chinese Medicine
| | - Peng Huang
- School of Pharmacy, Anhui University of Chinese Medicine
| | - Dianlei Wang
- School of Pharmacy, Anhui University of Chinese Medicine
| |
Collapse
|
3
|
Development of Duloxetine Hydrochloride Tablets for Delayed and Complete Release Using Eudragit L 100. INT J POLYM SCI 2021. [DOI: 10.1155/2021/8890503] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The purpose of the research was to optimize the preparation of duloxetine hydrochloride (duloxetine HCl) delayed release tablets. Duloxetine HCl produces a toxic substance called alpha-naphthol when duloxetine HCl is in contact with gastric fluid. Thus, duloxetine HCl when given orally needed a protective enteric coating that disable the delivery of duloxetine HCl in gastric fluid while enabling the drug delivery only in small intestine. Four different core tablets were prepared by direct compression technique, and the one which displayed quick disintegration and dissolution was chosen for enteric coating. The compressed tablets were enteric coated by dip coating technique. Since subcoating is required to safeguard the enteric coating, the core tablets were subcoated by using polymer HPMC K15M and then enteric coated with Eudragit L 100. The prepared tablets were assessed for the entire precompression and postcompression characteristics. FTIR study revealed the existence of all prominent peaks signifying its compatibility and authenticity. The in vitro studies showed that enteric-coated tablets were capable of restricting release in acidic media. The formulation F8 was optimised with 5% and 15% increase in weight of seal coat and enteric coat with good dissolution profile. Stability studies revealed that the optimized formulation was intact without any deterioration for 3 months. In conclusion, the optimized formulation could resist the drug release in acidic environment of gastrointestinal region and release the drug at a time once the tablet reaches the intestine.
Collapse
|
4
|
Yu J, Zhang Z, Li X, Singh RP, Liu Y, Hu L. Preparation and characterization of advanced resin based drug delivery system to improve therapeutic efficacy of huperzine A. J Drug Deliv Sci Technol 2021. [DOI: 10.1016/j.jddst.2021.102335] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Nagasamy Venkatesh D, Meyyanathan SN, Shanmugam R, Kamatham SS, Campos JR, Dias-Ferreira J, Sanchez-Lopez E, Cardoso JC, Severino P, Souto EB. Physicochemical, pharmacokinetic, and pharmacodynamic characterization of isradipine tablets for controlled release. Pharm Dev Technol 2020; 26:92-100. [PMID: 33074769 DOI: 10.1080/10837450.2020.1839495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Isradipine is a dihydropyridine calcium channel blocker (CCB) commonly used as vasodilator with antihypertensive properties. A remote-controlled release formulation for isradipine would substantially improve the clinical outcomes of the patients requiring chronic long-term treatment. In this work, sustained release (SR) tablets of isradipine, composed of hydroxypropylmethyl cellulose (HPMC), have been produced by wet granulation and their in vitro and in vivo characterization was compared to a conventional tablet dosage form of immediate release (IR) as preliminary assessment. Tablets composed of 15.0% (wt/wt) HPMC exhibited a SR profile over a period of 24 hours. The release of isradipine followed a Fickian diffusion pattern obeying to the first order kinetics and the extent of absorption was even higher in comparison to the developed conventional tablets, which showed immediate drug release. In vivo studies were carried out in rabbits, showing that the extent of isradipine absorption from the developed tablets was higher in comparison to IR tablets due to the modified release profile obtained for the former (p < 0.05). Our results suggest that SR tablets of isradipine are an efficient solid dosage form to overcome the limitations encountered in conventional IR tablets.
Collapse
Affiliation(s)
- D Nagasamy Venkatesh
- Department of Pharmaceutics, JSS College of Pharmacy (JSS Academy of Higher Education & Research), Ooty, Tamil Nadu, India
| | - S N Meyyanathan
- Department of Pharmaceutical Analysis, JSS College of Pharmacy (JSS Academy of Higher Education & Research), Ooty, Tamil Nadu, India
| | - R Shanmugam
- Department of Pharmaceutical Analysis, JSS College of Pharmacy (JSS Academy of Higher Education & Research), Ooty, Tamil Nadu, India
| | - S S Kamatham
- Sri Vasavi Institute of Pharmaceutical Sciences, Tadepalligudem, India
| | - J R Campos
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
| | - J Dias-Ferreira
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
| | - E Sanchez-Lopez
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.,Institute of Nanoscience and nanotechnology (IN2UB), University of Barcelona, Barcelona, Spain.,CIBERNED Centro de Biomedicina en Red de Enfermedades Neurodegenerativas, Instituto de Salud Juan Carlos III, Madrid, Spain
| | - J C Cardoso
- Tiradentes University (UNIT) and Institute of Technology and Research (ITP), Aracaju, Brazil
| | - P Severino
- Tiradentes University (UNIT) and Institute of Technology and Research (ITP), Aracaju, Brazil.,Tiradentes Institute, Dorchester, MA, USA
| | - E B Souto
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.,CEB - Centre of Biological Engineering, University of Minho, Braga, Portugal
| |
Collapse
|
6
|
Zhang XH, Zhou SL, Cai YQ, Xiao LT, Zhou H. Intestinal application of acid suppression drugs in patients with cerebral apoplexy: An analysis of 40 cases. Shijie Huaren Xiaohua Zazhi 2014; 22:4177-4180. [DOI: 10.11569/wcjd.v22.i27.4177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To assess the clinical effects of intestinal application of acid suppression drugs in patients with cerebral apoplexy.
METHODS: Eighty patients with cerebral apoplexy were randomly divided into either an observation group or a control group. Patients in the observation group were given rabeprazole by intestinal application, and patients in the control group were given omeprazole by intravenous drip. The gastric mucosal pH, serum prostaglandin E2 (PGE2) and epidermal growth factor (EGF) levels were tested and compared between the two groups.
RESULTS: Gastric mucosal pH values were increased 2 and 3 d after treatment, which were significantly higher in the observation group than in the control group (7.35 ± 0.09 vs 7.25 ± 0.08, 7.38 ± 0.06 vs 7.34 ± 0.08, P < 0.05). Gastric mucosal pH became normal 4 d after treatment. Serum PGE2 and EGF levels after treatment were significantly higher than those before treatment (P < 0.05). Serum PGE2 and EGF levels after treatment in the observation group were significantly higher than those in the control group (0.41 pg/mL ± 0.07 pg/mL vs 0.30 pg/mL ± 0.05 pg/mL, 79.5 pg/mL ± 10.83 pg/mL vs 60.53 pg/mL ± 9.93 pg/mL, P < 0.05).
CONCLUSION: Intestinal and intravenous application of acid suppression drugs can effectively prevent the occurrence of stress ulcer in patients with cerebral apoplexy, but intestinal application can inhibit gastric acid secretion earlier to promote the recovery of the gastric mucosa.
Collapse
|